Aarti Drugs Q1 Results Review - Miss On Operating Performance: Dolat Capital

Dolat Capital Report

Aarti Drugs Ltd.’s Q1 FY54 sales came in-line with our estimates, while Ebitda and profit after tax came below estimates on higher other expenses.

The company’s capex guidance for FY25 stands at Rs 2 billion, which will be funded through internal accruals and term loans. Ebitda margin guidance to be around 13-14% in H2 FY25.

We downward revise our FY25E/FY26E earnings per share estimates by -9.4%/- 1.3%, assuming lower-than-expected active pharma ingredient sales due to continued negative rate variance.

Maintain ‘Accumulate’ rating with revised target price of Rs 536 (earlier Rs 542) at 16 times FY26E price/earning.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.